# US 11,898,178 B2 · Catalysis deactivated angiotensin-converting enzyme 2 (ACE2) variants and their uses

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 11,898,178 B2
- Document ID: US11898178B2
- Status: Granted
- Kind: B2
- Application number: 17/823,066
- Filed: 2022-08-29
- Published: 2022-12-29
- Granted: 2024-02-13
- Earliest claimed: 2020-07-06
- Assignees: Avirmax, Inc.
- Applicants: Avirmax, Inc.
- Inventors: Shengjiang Liu
- Web page: https://patentgrep.com/patent/US11898178B2

## CPC

- C12N 9/485: {Exopeptidases (3.4.11-3.4.19)}
- A61P 31/14: for RNA viruses
- C12N 15/62: DNA sequences coding for fusion proteins
- C12N 15/86: Viral vectors
- C07K 2319/00: Fusion polypeptide
- C12Y 304/17023: Angiotensin-converting enzyme 2 (3.4.17.23)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12Y: ENZYMES

## Abstract

Angiotensin-converting enzyme 2 (ACE2) has been confirmed as a specific receptor for several β group coronaviruses include severe respiratory syndrome (SARS) coronavirus (SARS-CoV-1) and recently the causative agent for the World pandemic CoVID-19, SARS-CoV-2, and low pathogenic coronavirus of HCoV-NL63, a member in α-coronavirus group. Viral spike protein (S) of viral envelope is confirmed to bind to ACE2 as viral receptor to start a virus replication cycle. The present invention provides ACE2 and its mutants or variants, the viral or non-viral vectors thereof. Methods of treatment of viral infection of a human subject by using such mutants or variants are also provided.

## Claims

### Claim 1

An isolated polynucleotide comprising SEQ ID NOs: 64, 66, 67, 68, 69, 70, 72, 73, 74, 75, 76, 77, 78, 79, 80 or 81.

### Claim 2 (depends on 1)

A vector comprising the polynucleotide of claim 1.

### Claim 3 (depends on 2)

The vector of claim 2, wherein the vector is a viral vector.

### Claim 4 (depends on 3)

The vector of claim 3, wherein the viral vector further comprises the nucleotide sequence of an adeno-associated virus.

### Claim 5 (depends on 2)

The vector of claim 2, wherein the vector further comprises a plasmid, a nanoparticle, a liposome, a PEI derived or a colloid golden particle.